scholarly journals INFLUENCE OF OBSTETRIC GEL ON THE PROCESS AND DURATION OF LABOR

2021 ◽  
pp. 61-67
Author(s):  
S. Sh. Isenova ◽  
G. Zh. Bodykov ◽  
A.A. Altayeva ◽  
G.M. Isina
Keyword(s):  
Efficacy And Safety ◽  
Surgical Interventions ◽  
Obstetric Injuries

The article discusses the problems of weak labor, obstetric injuries, an increase in the number of surgical interventions. A study of the efficacy and safety of Dianatal obstetric gel when used in childbirth has been carried out.

VP101 Intrauterine Surgical Interventions: A Rapid Review

2019 ◽  
Vol 35 (S1) ◽  
pp. 97-97
Author(s):  
Aurelina Aguiar de Aguiar ◽  
Cecilia Farinasso ◽  
Daniela Rego ◽  
Luciana Simões ◽  
Camara Leão ◽  
...  
Keyword(s):  
Laser Ablation ◽  
Scientific Evidence ◽  
Perinatal Outcomes ◽  
Rapid Review ◽  
Cochrane Library ◽  
Efficacy And Safety ◽  
Ethical Aspects ◽  
Surgical Interventions ◽  
Adverse Conditions ◽  
Postnatal Mortality

IntroductionAdverse conditions during pregnancy, such as myelomeningocele (MMC), fetal-fetal transfusion syndrome (STFF) and congenital heart disease (CHD) not only significantly increase the risk of fetal death, but also increase the occurrence of severe postnatal sequelae.MethodsWe conducted a rapid review of the efficacy and safety of intrauterine interventions in MMC, STFF and DCC in comparison to traditional interventions. We searched Pubmed via Medline, Cochrane Library and Center for Reviews and Dissemination databases using the terms indexed and synonyms for each intervention.ResultsFor STFF, the available scientific evidence indicates that laser ablation is effective and presents better outcomes when compared to other interventions, such as high overall survival rate, better perinatal outcomes and less chance of brain injury. Even though intrauterine interventions in CHD present high rates of live births, high neonatal mortality rates are also reported. Evidence on the efficacy and safety of intrauterine surgical interventions for myelomeningocele and CHD is inconclusive. Regarding myelomeningocele, no significant differences were observed for the outcomes of postnatal mortality, rate of ventriculostomy placement, reversal of posterior brain herniation, motor response and placental rupture.ConclusionsThere is no consensus regarding the efficacy and safety of intrauterine surgical interventions for myelomeningocele and CHD. Regarding STFF, laser ablation is accepted as an effective intervention. It is necessary to conduct prospective studies in order to evaluate the effect of these interventions, considering the specifications of each condition and the ethical aspects.

scholarly journals Interventional Bronchus Occlusion Using Amplatzer Devices – A Promising Treatment Option for Children with Persistent Air Leak

2022 ◽  
Author(s):  
Katharina Schütz ◽  
Christoph M. Happel ◽  
Oliver Keil ◽  
Jens Dingemann ◽  
Julia Carlens ◽  
...  
Keyword(s):  
Treatment Option ◽  
Ventilatory Support ◽  
Lung Parenchyma ◽  
Efficacy And Safety ◽  
Air Leak ◽  
Chest Tubes ◽  
Surgical Interventions ◽  
Valuable Treatment ◽  
Promising Treatment ◽  
Persistent Air Leak

AbstractBackground: Persistent air leak (PAL) is a severe complication of secondary spontaneous pneumothorax (SSP). Surgical interventions are usually successful when medical treatment fails, but can be associated with significant complications and loss of potentially recoverable lung parenchyma. Methods: Retrospective analysis of efficacy and safety of interventional bronchus occlusions (IBO) using Amplatzer devices (ADs) in children with PAL secondary to SSP. Results: Six patients (four males, 4–15 years of age) underwent IBO using ADs as treatment for PAL. Necrotizing pneumonia (NP) was the most common cause (n=4) of PAL. Three patients were previously healthy and three suffered from chronic lung disease. All patients required at least two chest tubes prior to the intervention for a duration of 15–43 days and all required oxygen or higher level of ventilatory support. In three cases, previous surgical interventions had been performed without success. All children improved after endobronchial intervention and we observed no associated complications. All chest tubes were removed within 5–25 days post IBO. In patients with PAL related to NP (n=4), occluders were removed bronchoscopically without re-occurrence of pneumothorax after a mean of 70 days (IQR: 46.5–94). Conclusion: IBO using ADs is a safe and valuable treatment option in children with PAL independent of disease severity and underlying cause. A major advantage of this procedure is its less invasiveness compared to surgery and the parenchyma- preserving approach.

Real-World Preliminary Experience With Responsive Neurostimulation in Pediatric Epilepsy: A Multicenter Retrospective Observational Study

Neurosurgery ◽  
2021 ◽  
Author(s):  
Yasunori Nagahama ◽  
Thomas M Zervos ◽  
Kristina K Murata ◽  
Lynette Holman ◽  
Torin Karsonovich ◽  
...  
Keyword(s):  
Young Adults ◽  
Real World ◽  
Pediatric Epilepsy ◽  
Seizure Freedom ◽  
Drug Resistant ◽  
Efficacy And Safety ◽  
Seizure Reduction ◽  
Surgical Interventions ◽  
Significant Difference ◽  
Drug Resistant Epilepsy

Abstract BACKGROUND Despite the well-documented utility of responsive neurostimulation (RNS, NeuroPace) in adult epilepsy patients, literature on the use of RNS in children is limited. OBJECTIVE To determine the real-world efficacy and safety of RNS in pediatric epilepsy patients. METHODS Patients with childhood-onset drug-resistant epilepsy treated with RNS were retrospectively identified at 5 pediatric centers. Reduction of disabling seizures and complications were evaluated for children (<18 yr) and young adults (>18 yr) and compared with prior literature pertaining to adult patients. RESULTS Of 35 patients identified, 17 were <18 yr at the time of RNS implantation, including a 3-yr-old patient. Four patients (11%) had concurrent resection. Three complications, requiring additional surgical interventions, were noted in young adults (2 infections [6%] and 1 lead fracture [3%]). No complications were noted in children. Among the 32 patients with continued therapy, 2 (6%) achieved seizure freedom, 4 (13%) achieved ≥90% seizure reduction, 13 (41%) had ≥50% reduction, 8 (25%) had <50% reduction, and 5 (16%) experienced no improvement. The average follow-up duration was 1.7 yr (median 1.8 yr, range 0.3-4.8 yr). There was no statistically significant difference for seizure reduction and complications between children and young adults in our cohort or between our cohort and the adult literature. CONCLUSION These preliminary data suggest that RNS is well tolerated and an effective off-label surgical treatment of drug-resistant epilepsy in carefully selected pediatric patients as young as 3 yr of age. Data regarding long-term efficacy and safety in children will be critical to optimize patient selection.

ETODOLAC, A WELL KNOWN AND ACTIVELY USED DRUG IN DIFFERENT COUNTRIES OF THE WORLD. WOULD IT BE TIME FOR US?

2019 ◽  
Vol 57 (4) ◽  
pp. 468-473
Author(s):  
A. E. Karateev
Keyword(s):  
Pain Control ◽  
Low Frequency ◽  
Efficacy And Safety ◽  
Gastrointestinal Complications ◽  
Surgical Interventions ◽  
Inflammatory Agent ◽  
Nsaid Group ◽  
The World ◽  
Anti Inflammatory

Etodolac is a nonsteroidal anti-inflammatory drug (NSAID), a moderately selective cyclooxygenase-2 inhibitor, which has been already used in clinical practice for more than 30 years as a universal analgesic and anti-inflammatory agent. Etodolac has proven itself in relieving acute pain associated with injuries and surgical interventions (particularly in dentistry). However, the main point of application of etodolac is long-term pain control in chronic rheumatic diseases, such as osteoarthritis and rheumatoid arthritis. Numerous clinical trials have shown that etodolac is at least not inferior in its therapeutic effect to many other popular representatives of the NSAID group or exceeds them. The main advantage of etodolac is the low frequency of gastrointestinal complications. This review presents the basic data available in the literature on the efficacy and safety of etodolac.

scholarly journals Efficacy and safety of non-pharmacological, pharmacological and surgical treatment for hand osteoarthritis: a systematic literature review informing the 2018 update of the EULAR recommendations for the management of hand osteoarthritis

RMD Open ◽  
2018 ◽  
Vol 4 (2) ◽  
pp. e000734 ◽  
Author(s):  
Féline P B Kroon ◽  
Loreto Carmona ◽  
Jan W Schoones ◽  
Margreet Kloppenburg
Keyword(s):  
Literature Review ◽  
Systematic Literature Review ◽  
Task Force ◽  
Treatment Options ◽  
Risk Of Bias ◽  
Hand Osteoarthritis ◽  
Efficacy And Safety ◽  
Pharmacological Treatments ◽  
Surgical Interventions ◽  
Positive Results

To update the evidence on efficacy and safety of non-pharmacological, pharmacological and surgical interventions for hand osteoarthritis (OA), a systematic literature review was performed up to June 2017, including (randomised) controlled trials or Cochrane systematic reviews. Main efficacy outcomes were pain, function and hand strength. Risk of bias was assessed. Meta-analysis was performed when advisable. Of 7036 records, 127 references were included, of which 50 studies concerned non-pharmacological, 64 pharmacological and 12 surgical interventions. Many studies had high risk of bias, mainly due to inadequate randomisation or blinding. Beneficial non-pharmacological treatments included hand exercise and prolonged thumb base splinting, while single trials showed positive results for joint protection and using assistive devices. Topical and oral non-steroidal anti-inflammatory drugs (NSAIDs) proved equally effective, while topical NSAIDs led to less adverse events. Single trials demonstrated positive results for chondroitin sulfate and intra-articular glucocorticoid injections in interphalangeal joints. Pharmacological treatments for which no clear beneficial effect was shown include paracetamol, intra-articular thumb base injections of glucocorticoids or hyaluronic acid, low-dose oral glucocorticoids, hydroxychloroquine and anti-tumour necrosis factor. No trials compared surgery to sham or non-operative treatment. No surgical intervention for thumb base OA appeared more effective than another, although in general more complex procedures led to more complications. No interventions slowed radiographic progression. In conclusion, an overview of the evidence on efficacy and safety of treatment options for hand OA was presented and informed the task force for the updated European League Against Rheumatism management recommendations for hand OA.

Chronic rhinosinusitis with nasal polyps management in the age of biologics

2020 ◽  
Vol 41 (6) ◽  
pp. 413-419 ◽  
Author(s):  
Michael S. Blaiss
Keyword(s):  
Chronic Rhinosinusitis ◽  
Medical Management ◽  
Nasal Polyps ◽  
Inhaled Corticosteroids ◽  
Nasal Congestion ◽  
Standard Of Care ◽  
Efficacy And Safety ◽  
Polyp Size ◽  
Surgical Interventions

Background: Chronic rhinosinusitis is one of the most common medical conditions seen in the U.S. population. Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults has predominately a type 2 inflammatory endotype that usually is treated with medical management that consists of inhaled corticosteroids, saline solution irrigation, oral corticosteroid bursts, and, at times, leukotriene antagonists and antibiotics. If medical management fails, then surgical intervention is usually recommended. Various biologics that target type 2 inflammation are now available, which have been or will be approved for use in these patients. Objective: To determine where biologics that affect the type 2 pathway fit into the algorithm of treatment for CRSwNP. Methods: A review of the literature on standard-of-care measures and surgical interventions in CRSwNP and an analysis of recent studies on the efficacy and safety of biologics in this condition. Results: Standard of care with medication and surgical interventions fail in some patients with CRSwNP. Biologics that affect the type 2 inflammatory pathway led to a decrease in nasal polyp size, improved nasal congestion, and improved quality of life both in patients who had surgery and those who had not had surgery for CRSwNP. Also, they showed efficacy and safety in patients whether or not they had comorbid asthma. These agents do not cure the patient with CRSwNP, and will be required chronically for control. Conclusion: Shared decision-making should be used in determining the use of certain medications, surgical management, and biologics in patients with CRSwNP. In patients for whom surgery has already failed and in patients with moderate-to-severe CRSwNP who have other type 2 comorbidities, e.g., asthma, a trial of biologics is a rational course.

scholarly journals MODERN ASPECTS OF DIABETIC RETINOPATHY AND DIABETIC MACULAR OEDEMA TREATMENT

2012 ◽  
Vol 67 (1) ◽  
pp. 61-65 ◽  
Author(s):  
V. V. Neroev
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Central Zone ◽  
Laser Coagulation ◽  
Diabetic Patients ◽  
International Studies ◽  
Efficacy And Safety ◽  
Multicenter Studies ◽  
Surgical Interventions

Main reasons of eyesight deterioration in diabetic patients are diabetic retinopathy (DR) and diabetic macular oedema (DMO). International multicenter studies have shown that retinal laser coagulation in the event of DMO decreases the risk of eyesight loss in 50% , though only in 16% patients it was also possible to improve their eyesight. Use of vascular endothelial growth factor inhibitor – Ranibizumab – have opened a new era in DMA treatment. It’s efficacy and safety have been proven in several international studies. This article contains our own data upon the use of Lucentis in patients with DMO. Intravitreal Lucentis injections and subsequent retinal lasercoagulation in the macular zone were performed on 43 eyes; follow up period – 6 months. Additional injections were required in 19 cases, average amount of injections – 1,4. Mean corrected visual acuity before the treatment was 0,37±0,06, after7 days, 1, 3 and 6 months - respectively 0,41±0,06, 0,49±0,06, 0,51±0,07 and 0,52±0,07 (р0,05). Mean retina thickness in central zone was 428±25 mkm before treatment, 391±24 mkm 7 days after the last injection 349±23, 313±21 and 308±20mkm (р0,05) after 1, 3 and 6 months. In addition to that Lucentis use in preoperative period in patients with non-complicated proliferative DR allowed to decrease the risk of hemorrhagic complications. Thereby, intravitreal injections of Lucentis improve functional result of treatment of patients with DMO, increase efficacy and safety of surgical interventions in patients with complicated forms of proliferating DR.

A first approach to compare efficacy and safety of lepirudin and danaparoid in patients with heparin-induced thrombocytopenia (HIT)

2000 ◽  
Vol 10 (4) ◽  
pp. 325-325
Author(s):  
B. Farner ◽  
P. Eichler ◽  
H. Kroll ◽  
G. Urban ◽  
A. Greinacher
Keyword(s):  
Efficacy And Safety ◽  
Heparin Induced Thrombocytopenia
Sign in / Sign up

Export Citation Format

Share Document